Mendus AB (publ) Total Assets
Mendus AB (publ) total assets. Based on the latest financial reports, Mendus AB (publ) (IMMU) holds total assets worth Skr634.16 Million SEK (≈ $68.25 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Mendus AB (publ) (IMMU) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Mendus AB (publ) (2009–2025)
Total assets of Mendus AB (publ) from 2009 to 2025. This chart illustrates how Mendus AB (publ)'s total assets have evolved over time, based on quarterly financial data. See Mendus AB (publ) (IMMU) share price today for real-time trading data and today's change.
Mendus AB (publ) - Asset Composition Analysis
Mendus AB (publ) Total Assets Breakdown (December 2025)
Mendus AB (publ) total assets breakdown as of December 2025. Mendus AB (publ)'s total assets of Skr634.16 Million consist of 11.6% current assets and 88.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr64.66 Million | 10.3% |
| Accounts Receivable | Skr2.34 Million | 0.4% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr17.02 Million | 2.7% |
| Intangible Assets | Skr424.09 Million | 67.5% |
| Goodwill | Skr108.35 Million | 17.2% |
Asset Composition Trend (2009–2025)
This chart illustrates how Mendus AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IMMU current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mendus AB (publ)'s current assets represent 11.6% of total assets in 2025, a decrease from 83.6% in 2009.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, down from 82.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 84.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 67.5% of total assets.
Mendus AB (publ) Competitors by Total Assets
Key competitors of Mendus AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Mendus AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.53 | 3.16 | 11.28 |
| Quick Ratio | 1.53 | 3.16 | 12.10 |
| Cash Ratio | 0.00 | 2.47 | 10.11 |
| Working Capital | Skr27.90 Million | Skr73.84 Million | Skr215.14 Million |
Mendus AB (publ) - Advanced Valuation Insights
This section examines the relationship between Mendus AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.54 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -9.8% |
| Total Assets | Skr628.32 Million |
| Market Capitalization | $35.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mendus AB (publ)'s assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mendus AB (publ)'s assets decreased by 9.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mendus AB (publ) (2009–2025)
The table below shows the annual total assets of Mendus AB (publ) from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr628.32 Million ≈ $67.62 Million |
-9.77% |
| 2024-12-31 | Skr696.36 Million ≈ $74.94 Million |
-7.88% |
| 2023-12-31 | Skr755.95 Million ≈ $81.35 Million |
+21.85% |
| 2022-12-31 | Skr620.39 Million ≈ $66.76 Million |
-13.95% |
| 2021-12-31 | Skr720.98 Million ≈ $77.59 Million |
-1.05% |
| 2020-12-31 | Skr728.66 Million ≈ $78.42 Million |
+139.83% |
| 2019-12-31 | Skr303.83 Million ≈ $32.70 Million |
-32.54% |
| 2018-12-31 | Skr450.37 Million ≈ $48.47 Million |
+82.97% |
| 2017-12-31 | Skr246.15 Million ≈ $26.49 Million |
+102.47% |
| 2016-12-31 | Skr121.57 Million ≈ $13.08 Million |
-21.18% |
| 2015-12-31 | Skr154.24 Million ≈ $16.60 Million |
+117.14% |
| 2014-12-31 | Skr71.03 Million ≈ $7.64 Million |
-35.15% |
| 2013-12-31 | Skr109.54 Million ≈ $11.79 Million |
+310.31% |
| 2012-12-31 | Skr26.70 Million ≈ $2.87 Million |
+187.86% |
| 2011-12-31 | Skr9.27 Million ≈ $998.01K |
+48.46% |
| 2010-12-31 | Skr6.25 Million ≈ $672.23K |
-18.69% |
| 2009-12-31 | Skr7.68 Million ≈ $826.76K |
-- |
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more